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Abstract: Magnesium (Mg) is an essential mineral in the body, impacting the synthesis of
biomacromolecules, bone matrix development, energy production, as well as heart, nerve, and muscle
function. Although the importance of Mg is evident, reference values for serum Mg (sMg) in pediatric
patients (more specifically, in neonates) are not well established. This systematic literature review
and meta-analysis (using 47 eligible studies) aims to quantify normal and tolerable ranges of sMg
concentrations during the neonatal period and to highlight the factors influencing Mg levels and
the importance of regulating sMg levels during pregnancy and birth. In newborns without Mg
supplementation during pregnancy, magnesium levels at birth (0.76 (95% CI: 0.52, 0.99) mmol/L) were
similar to that of mothers during pregnancy (0.74 (95% CI: 0.43, 1.04) mmol/L), but increased during
the first week of life (0.91 (95% CI: 0.55, 1.26) mmol/L) before returning to adult levels. This pattern
was also seen in newborns with Mg supplementation during pregnancy, where the average was 1.29
(95% CI: 0.50, 2.08) mmol/L at birth and 1.44 (95% CI: 0.61, 2.27) mmol/L during the first week of life.
Factors influencing these levels include prenatal Mg supplementation, gestational age, birth weight,
renal maturity/function, and postnatal Mg intake. Elevated Mg levels (>2.5 mmol/L) have been
associated with an increased risk of mortality, admission into intensive care, hypotonia, hypotension,
and respiratory depression but sMg concentrations up to 2.0 mmol/L appear to be well tolerated in
neonates, requiring adequate survey and minimal intervention.
Keywords: systematic literature review; meta-analysis; magnesium; neonates; cord blood; nutrition;
supplementation
1. Introduction
Magnesium, the fourth most abundant cation in the body [1], plays a crucial role in many
physiologic functions. It contributes to bone matrix development and is required for the synthesis
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of biomacromolecules, including DNA, RNA, and proteins [2–4]. It is needed for energy production
and glycolysis [2,4–6]. Magnesium is also utilized for electrostatic stabilization in cell systems
and participates in the regulation of active transport of calcium and potassium ions across cell
membranes [7–10], thereby regulating muscle contraction, nerve impulse conduction, vascular
tone, and normal heart function. Magnesium homeostasis is largely controlled by the kidney,
with reabsorption occurring predominantly in the thick ascending limb of the loop of Henle (70–80%)
and, to a lesser extent (10–15%), in the distal convoluted tubule [11]. It is regulated by many hormonal
and nonhormonal factors, and reabsorption is closely linked to that of calcium [11].
Evaluation of serum magnesium (sMg) is the most common method of assessing magnesium
concentration in clinical practice [12], despite the fact that it may not accurately reflect total body
magnesium content—only approximately 1% of total body magnesium is in serum and interstitial
body fluid, with the remainder in bone, muscle, and soft tissue [1]. Reference values for sMg in adults
are well defined (0.75 mmol/L; 95% CI: 0.45, 1.05) [13,14]. By contrast, in pediatric patients—and more
specifically in newborn and preterm infants (<37 weeks gestation [15])—reference values are either not
available or are very limited and still controversial; most laboratories do not provide specific reference
intervals for this population.
Until recently, sMg concentration was scarcely included in the biological survey of newborn infants
unless hypomagnesemia was suspected in association with persistent and refractory hypocalcemia [11].
Serum magnesium assessment has become more frequently requested due to the more regular
early use of magnesium in balanced parenteral nutrition providing electrolytes and minerals for
very-low-birth-weight (VLBW) infants; and the use of antenatal magnesium administration for
neuroprotection in very preterm infants (<32 weeks gestation [15]) and/or for the prevention of
eclampsia in preeclamptic mothers. Thus, there is a need for normative data and the determination
of an upper tolerable level of sMg concentration in preterm and term infants. In 2012, the Canadian
Laboratory Initiative in Pediatric Reference Intervals (CALIPER) project proposed new reference
ranges for neonates that were developed using the CALIPER database, which included data from
healthy infants and children in the community (1072 male and 1116 female; newborn to 18 years) [16].
CALIPER data suggested that sMg levels in healthy term infants during the first two weeks after
delivery were higher than adult reference values and decreased progressively during the remainder of
the first year of life to adult levels. Although analytical methods and reagents have changed since the
time of this study, the provided ranges are useful for understanding changes in magnesium levels that
occur during this time period.
Magnesium requirements in preterm infants remain poorly defined. Fetal accretion of magnesium
occurs throughout pregnancy, with accretion rates reportedly ranging from 3 to 5 mg/kg/day
(0.12–0.20 mmol/kg/day) during the third trimester [17]. Data derived from the chemical analysis
of fetuses from 24 to 40 weeks of gestation demonstrated gradually increasing rates of magnesium
accretion [18]. Preterm infants exhibit particularly high growth velocity, and they miss at least some of
the period of high in utero accretion of magnesium; therefore, it is likely that magnesium requirements
of preterm infants are different than those of infants delivered at full term.
The primary objectives of the current review are to examine magnesium levels in preterm infants
during the neonatal period (0–28 days); explore major potential factors influencing magnesium
concentration (i.e., gestational age, magnesium supplementation during pregnancy, postnatal
magnesium intakes, and renal function) in an effort to better understand magnesium replacement
requirements; and discuss reference sMg concentrations in preterm infants. As a secondary objective,
this review evaluated the potential side effects of increased sMg in order to discern the upper tolerable
levels in preterm infants during the first weeks of life.
2. Materials and Methods
To find relevant published literature on magnesium levels, a search was conducted on PubMed
that included terms for the type of patient (e.g., human, newborn, and infant), stage of care (e.g.,
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prenatal, antenatal, and neonatal), and type of treatment/measures (e.g., magnesium, magnesium
sulfate (MgSO4), nutrition, nutritional status, and nutritional sciences) and included articles published
up to June 2014. A total of 322 articles were found. Article titles and abstracts were reviewed
(3 contributors) for potential relevancy, and 143 were excluded; papers were excluded at this stage
if they were review articles, if the study was in non-healthy infants, and if mineral concentrations
were not a part of the focus. The full texts of the remaining 179 studies were reviewed and 51 were
eligible as they reported magnesium levels in preterm and/or term infants before, at, and/or after
birth. Studies were excluded if they reported mean magnesium levels that were clearly outliers among
the collected data based on clinical expert opinion (JR); this included 4 studies [19–22].
The remaining 47 studies were used in meta-analyses to derive an estimated global mean and
95% confidence interval (CI) of the population concentration range using only studies reporting
both mean and standard deviation data. Populations of interest included: healthy pregnant women
without magnesium supplementation during pregnancy and healthy newborns with and without
magnesium supplementation during pregnancy. In each meta-analysis, studies were weighted based
on the number of sMg samples collected. In studies reporting both venous and arterial blood
levels, the venous levels were used for the meta-analysis. Heterogeneity was quantified using the I2
statistic [23]. Magnesium data reported in non-SI units were converted to millimoles by multiplying
by the appropriate conversion factor.
Additional information from other studies found from the reference lists of reviewed papers and
articles not reporting exact magnesium levels was included to bolster the evidence. To increase the data
available for preterm infants during the first week of life, the primary authors of four recent clinical
studies in preterm infants (Drs. F. Bonsante, S. Iacobelli, S.J. Moltu, V. Christmann, and S. Marret)
provided additional information on the sMg concentrations and/or intakes, as well as recorded during
their studies [24–29]. This complementary information was included in the present manuscript.
Meta-analyses were conducted with OpenMeta[Analyst] (Brown University, Providence, RI, USA),
a program funded by AHRQ (grant number: R01HS018574; available at http://www.cebm.brown.
edu/openmeta/index.html), using a continuous random-effects model at the 95% confidence level.
3. Results
3.1. Maternal Magnesium Concentrations
In normal pregnancy, maternal sMg decreases. However, the exact time course of these changes
has yet to be established [30]. Published data from pregnant women are presented in Table S1. In those
studies, mean sMg concentration in mothers ranged from 0.59 mmol/L to 0.95 mmol/L during
gestation [31–45], from 0.54 mmol/L to 0.86 mmol/L before or during labor [31,35,40,41,43,46–49],
and from 0.54 mmol/L to 0.90 mmol/L at delivery [24,35,36,42,48,50–63].
Although the heterogeneity of the included studies was high (I2 = 99.6%; p < 0.001),
the meta-analysis performed on 31 studies including 2395 mothers revealed a mean estimate of
0.74 mmol/L (95% CI: 0.43, 1.04) in pregnant women around delivery (Figure 1). For the studies not
included in the meta-analysis [33,42,45], the mean (or median) reported magnesium level falls within
the derived 95% CI, as well as the reported ranges.
Ranges of magnesium concentrations reported in healthy pregnant women without magnesium
supplementation differ to the normal reference interval reflecting an adequate magnesium status
for healthy adults (0.75–0.95 mmol/L) [64]. Changes in magnesium status in pregnant women
may translate into effects on glucose metabolism, blood pressure, and the contractile response of
uterine muscle. Thus, earlier reductions in maternal magnesium have been associated with an
increased incidence of gestational diabetes [65–67] and may contribute to both preterm delivery and
preeclampsia [36,68,69]. Few well-designed trials have examined the impact of dietary magnesium
supplementation in pregnant women; thus, the benefits and risks of such remain controversial [70].
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By contrast, MgSO4 supplementation in pregnant women experiencing preterm labor or preeclampsia
has been more thoroughly studied in randomized trials. In these studies, the target sMg in the mother
before delivery was between 2.0 and 3.5 mmol/L [71] and meta-analyses of these data suggest that these
levels have a neuroprotective effect [72,73]. However, very few studies report the sMg concentrations in
the mothers receiving MgSO4 supplementation during pregnancy (e.g., Marret et al. [24]).
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interval, SD: standard deviation. 
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3.2. Magnesium Levels at Birth in Neonates without Magnesium Supplementation during Pregnancy
Reference ranges for sMg levels in preterm infants are difficult to pinpoint because a limited
number of studies evaluate the sMg concentration in healthy preterm and term infants during the
first week of life. Some data have been published on the cord blood from healthy preterm and term
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infants and can be utilized to estimate early neonatal levels. In addition, data on sMg levels in cord
blood and during the early neonatal period are available in preterm infants included in randomized
control trials evaluating the effect of maternal magnesium administration before delivery for tocolysis,
for prevention or treatment of eclampsia, or for neuroprotection against cerebral palsy. In these studies,
the control group may represent normative neonatal levels whereas the treatment group may be
evaluated to discern upper tolerable levels or potential side effects of magnesium overload (Table S2;
Figure 2) [24,34,35,40–43,46–53,57–60,63,74–81].
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lt the heterogeneity of the included studies was high (I2 = 98.3%; p < 0.001),
the meta-analysis performed on 22 studies including 2766 infants revealed a mean esti ate of
0.76 mmol/L (95% CI: 0.52, 0.99) in neonates at delivery (Figure 2). For the studies not included
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in the meta-analysis [42,46,77,79,81], the mean (or median) reported magnesium level falls within the
derived 95% CIs, as well as the reported ranges, except for Stigson et al. (1997), which reported a wider
range (possibly due to a lack of exclusion criteria relevant to medical conditions) [81].
These mean values are similar to that observed in mothers during pregnancy, failing to
demonstrate a distinct relationship between gestational age and neonatal magnesium concentration.
However, magnesium crosses the placental barrier actively [11,82], and magnesium levels in neonates
tend to reflect maternal magnesium concentrations, regardless of magnesium exposure during
pregnancy (Table 1) [24,35,40,42,47–53,59,60,63,79,83–85]. Supporting data are provided in studies
conducted in term neonates without magnesium supplementation during pregnancy [42,49,50], as well
as in studies conducted in both preterm and term neonates with magnesium supplementation during
pregnancy [79,83,85]. The results from the study by Marret et al. (2008) also support the positive
relationship between magnesium levels in cord blood and maternal blood [24]. Although the influence
of other maternal factors (e.g., method of delivery and multiple gestations) have been proposed [21],
their role in predicting neonatal magnesium concentrations has not been confirmed. As suggested
for sMg concentration in healthy pregnant women without magnesium supplementation, the cord
blood mean (and 95% CI) for total sMg concentration could differ from the normal reference interval
reflecting an adequate fetal status.
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Table 1. Studies reporting relationship between maternal and umbilical cord blood and/or serum magnesium concentrations in newborns without and with
magnesium supplementation during pregnancy.
Study Population (n) Sampling Method Maternal Magnesium Level,Mean± SD, mmol/L
Neonatal Magnesium Level,
Mean± SD, mmol/L Correlation
No magnesium supplementation
Kozielec 2004 [50]
Term infants (38–41 weeks (72))
and mothers (75) derived from
population of mothers (83) and
neonates
At delivery, 2 mL maternal
venous blood and 5 mL cord
blood
0.89 ± 0.13 0.97 ± 0.16 r = 0.52p = 0.000006
Marret 2008 [24] Preterm infants (23–32 weeks(92)) and mothers (92)
At delivery; mothers blood
serum and venous cord blood 0.78 ± 0.11 0.83 ± 0.13
r = 0.36
p = 0.0004
Schulpis 2010 [48]
Term infants and mothers
- Vaginal delivery (16)
- Scheduled cesarean delivery (14)
Mothers at the beginning of
delivery; cord blood within 3–4
min of delivery
0.81 ± 0.09
0.81 ± 0.04
0.81 ± 0.04
0.80 ± 0.02
r = not provided p > 0.05
r = not provided p > 0.05
Vobecky 1982 [49] Mothers (550) and healthy terminfants (505)
Maternal venous blood
obtained during delivery;
mixed venous-arterial cord
blood at delivery
0.68 ± 0.13 0.69 ± 0.13 r = 0.64p < 0.01
Magnesium supplementation
Borja-Del-Rosario 2014 [83] Preterm infants 24–32 weeks (192)and their mothers
Maternal serum within 6 h
before delivery; neonatal serum
24 h post-delivery
2.30 ± 0.51 1.52 ± 0.43 r = 0.10p = 0.15
Marret 2008 [24] Preterm infants (23–32 weeks(119)) and mothers (119)
At delivery; mothers blood
serum and venous cord blood 0.77 ± 0.129 1.0 ± 0.193
r = 0.23
p = 0.012
Rudnicki 1991 [79]
Women (12) with
pregnancy-induced hypertension
and their infants (gestational age,
37–39 weeks)
Mothers prior to delivery;
arterial blood from cord 0.74 (0.71, 0.81)
1 0.80 (0.70, 0.91) 1
r = 0.77
p < 0.02
Schanler 1997 [85]
Women in preterm labor (16) and
their infants (22); mean
gestational age, 31.7 ± 2.6 weeks
At delivery; peripheral venous
blood from mothers and infants Not provided (figure only) Not provided (figure only)
r = 0.61
p = 0.004
1 Median (95% confidence interval). Magnesium concentrations reported in non-SI units have been converted to mmol/L as follows: mg/dL × 0.411; mEq/L × 0.5.
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3.3. Magnesium Levels at Birth in Neonates with Magnesium Supplementation during Pregnancy
Data from available studies of neonates receiving magnesium administration during pregnancy are
summarized in Table S3, with considerable across-study variation in magnesium regimen. Magnesium
levels were, not surprisingly, generally higher among infants with administered magnesium during
pregnancy compared to those without supplementation, with emphasis on the extent of cumulative
intake provided before delivery. Average cord blood sMg concentrations drawn at delivery ranged from
0.80 to 1.80 mmol/L in studies of magnesium supplementation for pregnancy-induced hypertension
(PIH), fetal neuroprotection, or prevention of eclampsia [24,40,79,86–89].
In the study by Rudnicki et al. (1991), which reported 0.80 mmol/L at delivery in term infants
of mothers with PIH, mothers received a 48-h intravenous infusion (50 mmol of MgCl2 during the
first 24 h followed by 12 mmol of MgCl2 during the second 24 h), followed by 15 mmol/d until one
day after delivery, with a median duration of 12 days (range: 3–23 days) [79]. This was a low-dose
magnesium regimen, which may explain why the level at delivery was similar to corresponding levels
seen in term infants without magnesium supplementation during pregnancy.
In two studies for preterm neuroprotection [24,87], the average magnesium concentrations
were 1.00 mmol/L and 1.30 mmol/L, which seem to reflect the infant’s exposure to magnesium
administration in women at risk of imminent very preterm birth. In the PREMAG study, which reported
a mean sMg of 1.00 ± 0.22 mmol/L at birth (n = 191), mothers received MgSO4 as a single injection
of 0.1 mg/L (4 g, 33.23 mmol) over 30 min within 24 h of expected delivery. In contrast, in the study
by Palatnik et al. (2015), which reported a mean of 1.30 mmol/L at birth, mothers received at least a
loading dose of 6 g (49.85 mmol) infused for 20–30 min, followed by a maintenance infusion of 2 g/h
(16.62 mmol/h) for up to 12 h [87]. In this study, infusion was discontinued if delivery was no longer
imminent, but would be resumed if the anticipated delivery was at less than 34 weeks gestation.
The other 2 studies reported magnesium concentrations in infants with preeclamptic mothers
who received magnesium supplementation for prevention of eclampsia [40,86]. Although the severely
preeclamptic mothers in the study by Katz et al. (2012) received MgSO4 prior to delivery, the regimen
was unspecified; the resulting sMg level in venous umbilical cord blood was 1.37 mmol/L [40].
The mean sMg level in term infants whose mothers received MgSO4 supplementation in the study by
Boriboonhirunsarn et al. (2012) was 1.80 mmol/L at delivery [86]. The magnesium regimen for these
mothers included a loading dose of 4 g (33.23 mmol) of MgSO4 followed by continuous intravenous
infusion of 2 g/h (16.62 mmol/h), with dose adjustments performed depending on if the magnesium
level was within therapeutic range (2.0–3.5 mmol/L) and on clinical signs and symptoms. The total
dose ranged from 5.5 g (45.69 mmol) to 34.5 g (286.62 mmol), with a mean of 14.4 g (119.63 mmol) [86].
Although the heterogeneity of the included studies was high (I2 = 99.1%; p < 0.001), the meta-
analysis performed on six studies including 992 preterm and term infants revealed a mean estimate of
1.29 mmol/L (95% CI: 0.50, 2.08) at delivery in neonates with exposure to magnesium supplementation
at the end of pregnancy (Figure 3). The study by Rudnicki et al. (1991) was not included in the
meta-analysis (as it did not report mean values in infants from healthy mothers) and reported a median
sMg level of 0.80 mmol/L at delivery in term infants of mothers with PIH [79]. In comparison to the
meta-analysis results, this median value is more similar to infants without magnesium supplementation
during pregnancy, which may be related to the relatively low dosing regimen employed by the Rudnicki
et al. (1991) study in comparison to the others, as well as the fact that the study used a different type of
magnesium supplementation formula (MgCl2 vs. MgSO4).
Neonates receiving magnesium supplementation during pregnancy have higher reported
concentrations of magnesium at birth than infants with no exposure, regardless of gestational
age and indication for treatment. Variability in reported levels may be related to the duration of
supplementation during pregnancy, the total dose of magnesium received, and the delay between
last supplementation dose and delivery, as well as other heterogeneous characteristics among
study populations.
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infants that did not rec ive magnesium supplementation during pregnancy, the reported mean
sMg levels from the 6 studies included in the meta-analysis r nged from 0.72 to 1.10 mmol/L within
24 after delivery [24,63,74,79], from 0.94 to 0.97 mmol/L at 48 h after delivery [77,78], and from
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ri the first days of life. In the largest study, mean magnesium concentration increased
from birth (0.68 mm l/L) to Day 5 of life (0.79 mmol/L) [49]. Other studies that demonst ated
a increa e in magnesium level include those by Marret et al. (2008), Schauberger et al. (1979),
and Meht et al. (2007). Marret et al. (2008) reported significant mean increase from 0.81 mmol/L
at birth to 0.96 mmol/L, (p = 0.001) 24 h after del very in preterm infants [24]. For preterm and term
fants eval ated in the Schauberger et al. (1979) and Mehta et al. (2007) studi s, the increases i mean
magnesium levels at 24 h and at 36–48 h aft r deliver , resp ctively, were very small (difference of
0.01 mmol/L for both populatio s) [63,78]. An interesting result was found in he Hillman et al. (1977)
study, which report d an increase in mean magnesium levels from birth to 48 ± 2 h post-deliv ry in
both preterm and term infant ; however, at s ven days of life, th mean sMg level for term infants
decrea ed, whil me n sMg concentration for pre erm infants continued to increase [77]. Three studies
found f om the literature search, but whi h w re ot included in the meta-analysis, also show different
variation in mag esium changes. Rudnicki et al. (1991), which was not included because it provided
only median value for infants delivered by mothers with PIH, demonstrated a decrease i
Nutrients 2017, 9, 1125 10 of 24
magnesium levels from birth (0.77 mmol/L) to 24 h postpartum (0.72 mmol/L) [79]. In a small study by
Schanler et al. (1997), which did not provide raw data, sMg concentrations in infants not administered
magnesium during pregnancy remained at approximately 1 mmol/L during the first 72 h of life, with a
slight downward trend [85]. According to data from the CALIPER database, which combined data for
newborns aged 0–14 days, magnesium concentrations in healthy newborns initially increased during
the first days of life, then steadily decreased progressively during the second week of life to reach adult
levels [16]. These discrepancies may be related to heterogeneity among the populations, including
postnatal magnesium intake, renal function maturation, gestational age, and birth weight.
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study eem to be the res lt of the lower cum lative magnesium intake provid d before delivery [24,79].
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levels at 24 h, mothers received a loading dose of 4–6 g (33.23–49.85 l) or 6 g (49.85 mmol),
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Similar to levels reported in infants without magnesium supplementation during pregnancy,
these studies varied in demonstrating a distinct trend in the change in magnesium concentration from
birth during the first days of life. The results of the meta-analyses suggest that sMg levels in infants
increase during the first day of life (mean cord blood Mg concentration at birth, 1.25 mmol/L; mean sMg
concentration at 24 h, 1.48 mmol/L), aligning with the results of the meta-analyses in neonates that
did not receive magnesium administration during pregnancy. Two of the studies reported a small
positive change in mean magnesium concentration between birth and at 24 h post-delivery [24,79].
In the study by Marret et al. (2008), sMg increases from 0.99 mmol/L at birth to 1.07 mmol/L
(p = 0.001) 24 h after delivery [24]. In addition, both studies demonstrated larger first-day average
magnesium concentration in infants with supplementation compared to those without [24,79]. In the
study by Schanler et al. (1997), sMg concentrations demonstrated an overall negative trend from birth
(approximately 1.75 mmol/L) to 72 h (approximately 1.46 mmol/L) [85]. In this study for tocolysis,
mothers received a loading dose of 6 g (49.85 mmol) of MgSO4 over 30 min, followed by a maintenance
dose of 2 g/h (16.62 mmol/h; titrated from 1.5 to 3 g/h (12.46–24.92 mmol/h) depending upon uterine
activity) until within 60 min of birth or at the time of the C-section, with a mean administration of 26
days (range: 8–63) [85].
Notably, a relationship between the extent of magnesium exposure (dosage) and neonatal
magnesium has been documented in two of these studies [83,85]. Borja-Del-Rosario et al. (2014) reported
significant correlations between the total maternal magnesium dose at 24 and 48 h of infusion and
neonatal sMg concentrations (r = 0.55 (p < 0.0001) and r = 0.35 (p < 0.0001), respectively) [83]. Similarly,
Schanler et al. (1997) described a significant positive correlation between maternal MgSO4 dosage and
neonatal sMg concentration (r = 0.74; p < 0.001) when MgSO4 was administered for preterm labor [85].
3.5. Factors Contributing to Magnesium Levels in Neonates during the First Days of Life
As demonstrated in the previous sections, magnesium supplementation during pregnancy is highly
correlated with neonatal sMg levels. After birth, many other factors contribute to influencing neonatal
sMg levels, including postnatal magnesium intake, renal function, gestational age, and birth weight.
In preterm infants, magnesium nutritional supply can be provided parenterally during the
first days of life followed by a progressive introduction of enteral nutrition as human milk or
formula. In parenteral nutrition, agnesium intake is fully available for mineral metabolism and
magnesium homeostasis. With enteral nutrition, the intestinal magnesiu absorption is limited
among newborns but may be higher in preterm versus term infants [11]. Magnesiu retention
may also be higher in preterm versus term infants and may exceed the apparent intrauterine
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retention rates [90]. In term infants, breast milk provides approximately 5.5–7.5 mg/kg/day
(0.23–0.31 mmol/kg/day) of magnesium [17]. By contrast, amounts of magnesium provided by
enteral or parenteral nutrition in preterm infants vary, depending on the preparation(s) administered.
With fortified human milk or formula mean magnesium intakes range from 6.0 to 12.0 mg/kg/day
(0.25–0.5 mmol/kg/day), absorption rate around 50%, and mean retention accounted from 1.8 to
3.6 mg/kg/day (0.08–0.15 mmol/kg/day) [11].
Magnesium levels among newborn infants, especially VLBW infants, change rapidly during the
first days of life as a result of the early parenteral and enteral magnesium intakes and the maturation
of the glomerular filtration rate. After a few days, sMg levels decrease progressively to reach a plateau
at the end of the first month of age. Indeed, renal immaturity is observed at birth and renal function
improves progressively during the first weeks of life. In VLBW infants, renal function is directly
related to gestational age and inversely related to postnatal age as illustrated by the serum creatinine
concentration [91]. There is a progressive maturation of the glomerular filtration rate increasing
during the first weeks of life. Tubular reabsorption of magnesium is high but the serum threshold
of urinary excretion is not well defined in VLBW infants [92,93]. Medications for patent ductus
arteriosus (e.g., indomethacin, ibuprofen, acetylsalicylic acid) affecting renal perfusion can potentially
influence magnesium handling [94,95]. Additionally, changes in hormonal and nonhormonal factors
(e.g., calcium) can potentially contribute to magnesium homeostasis and sMg levels.
Data from studies conducted in VLBW infants are often confounded by postnatal parenteral
magnesium supplementation. In a time-course study of magnesium homeostasis, extremely low
birth weight infants with a birth weight (<1000 g; n = 51) received a parenteral solution providing
0.15 mmol/kg/day of magnesium. Mean sMg increased during the first week of life (from 0.85
± 0.14 mmol/L on Day 1 to 1.09 ± 0.10 mmol/L on Day 4), then decreased progressively (to
0.89 ± 0.08 mmol/L on Day 21 and to 0.91 ± 0.10 mmol/L on Day 28) [96]. This trend may be
strongly influenced by glomerular function. During the first week, the sMg concentration ranged
from 0.62 mmol/L to 1.53 mmol/L, but four out of five infants with magnesium levels higher than
1.3 mmol/L had evidence of acute kidney injury, defined as serum creatinine concentration greater
than 1.5 mg/dL (132 mmol/L). In this study, higher sMg concentration appears to be related to birth
weight (<750 g) and/or gestational age (<27 weeks) [96].
Additional data were obtained from nutritional intervention studies evaluating the effect of
early aggressive parenteral nutrition in VLBW infants by direct contact with the primary authors
(Figure 6) [25–29,97]. The first study was a randomized controlled trial that evaluated the effect of two
diets (parenteral plus enteral) on postnatal growth and included 48 VLBW neonates (<1500 g) in two
groups of 24 infants [25]. The starting parenteral solutions contained 0.23 mmol/dL and 0.20 mmol/dL
of Mg for the two groups. The mean parenteral magnesium intake was 0.084 ± 0.034 mmol/kg/day
and 0.093 ± 0.030 mmol/kg/day in the intervention and control group, respectively (p = 0.18). Mean
sMg levels reported at Day 3 of life were 0.91 ± 0.13 mmol/L (n = 22) and 0.96 ± 0.12 mmol/L (n = 21),
respectively. During the first week of life in the whole population, the mean sMg concentrations were
0.93 ± 0.12 mmol/L (n = 75) [25] (Figure 6). Prenatal magnesium exposure was not part of the data
collected in this study; however, based on reviewing the magnesium data, the authors believe that
although it is possible some of the infants could have received prenatal magnesium supplementation,
the number of these patients is minimal and would not be expected to significantly alter the results
and interpretations of the current analysis.
The second nutritional intervention study was a cohort study evaluating the effect of increasing
protein intake during the first days of life in VLBW infants [27,97]. Serum magnesium concentration
was included in the biological survey during the first week of life. In all, 226 sMg concentrations were
recorded in 76 preterm infants <33 weeks gestational age. Parenteral nutrition was provided from
birth and magnesium after the second day of life. Mean magnesium parenteral intake during the first
week of life averaged of 0.11 mmol/kg/day of magnesium, with a maximum intake of 0.36 mmol/kg.
Mean sMg concentration during the first week of life was 0.94 ± 0.15 mmol/L (range: 0.56–1.35)
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(Figure 6). In this study, the sMg levels increased progressively until day 5 and decreased thereafter.
In addition, the mean sMg concentrations were significantly related to the parenteral magnesium
intake [27,97]. The last study compares two successive cohorts of VLBW infants receiving different
nutritional intakes. Both cohorts received parenteral nutrition, with the second cohort receiving
higher concentrations of protein as well as minerals (including magnesium) [28,29]. For cohort 1,
the maximum parenteral intake of magnesium was 0.14 mmol/kg/day while the maximum intake in
cohort 2 was 0.3 mmol/kg/day. In preterm infants without prenatal magnesium supplementation,
mean sMg concentration during the first week of life was 0.87 ± 0.15 mmol/L (n = 64; 377 samples)
in cohort l and 0.96 ± 0.15 mmol/L (n = 66; 435 samples) in cohort 2 (Figure 6). In both groups, the
mean sMg level increased up to the Day 4 of life; however, the sMg concentration from Day 1 to Day
7 in cohort 2, was significantly higher than that in cohort 1 in relation to the higher parenteral Mg
intakes. In this study, sMg concentrations were also obtained during the first week of life in 17 infants
with prenatal magnesium supplementation. Mean sMg concentration reached 1.35 ± 0.44 mmol/L
(n = 114), but decreased progressively from birth to the end of the first week of life.
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Although the heterogeneity of the included studies was significant (I2 = 62.8%, p = 0.045), the 
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Although the heterogeneity of the included studies was significant (I2 = 62.8%, p = 0.045),
the meta-analysis performed on four studies including 301 infants mainly without prenatal magnesium
supplementation and 1427 evaluations during the first week of age revealed a mean estimate of
0.94 mmol/L (95% CI: 0.66, 1.22) in VLBW infants receiving total or partial parenteral nutrition
(Figure 6).
Data during the second and third weeks of life were obtained from the Noone et al. (2012) and
Christmann et al. (2013; 2014) studies. In the study by Christmann et al. (2013; 2014), where enteral
nutrition accounted for more than 50% of magnesium intake, mean sMg was similar in both cohorts.
In cohort 1, sMg decreased respectively to 0.89 ± 0.12 mmol/L (n = 172) and 0.87 ± 0.07 mmol/L
(n = 58) in cohort 1 and to 0.91 ± 0.10 mmol/L (n = 88) and 0.86 ± 0.08 mmol/L (n = 16) in cohort
2 [28,29]. Similarly, Noone et al. (2012) reported a mean value of 0.91 ± 0.10 mmol/L (n = 51) and 0.89
± 0.08 mmol/L (n = 51) during the second and the third week of life respectively [96].
Thus, the results from the Noone et al. (2012) and Christmann et al. (2013; 2014) studies in VLBW
infants during the first month of life support the results from the large database of Colantonio et al.
(2012), which found that magnesium concentrations in healthy newborns initially increased during the
first week of life, before steadily decreasing to adults levels [16].
Nutrients 2017, 9, 1125 14 of 24
In summary, the results of this review of magnesium levels during the first month of life in
preterm infants and VLBW infants receiving nutritional intervention were similar to the data observed
in term infants suggesting that sMg concentration increases during the first week of life to a level higher
than the adult reference values and decreases to adult levels thereafter. These early changes are likely
influenced by many factors, including postnatal magnesium intake, gestational age, and renal maturity.
3.6. Benefits and Risks of Elevated Neonatal Serum Magnesium
3.6.1. Benefit: Neuroprotection
Magnesium supplementation via magnesium administration during pregnancy may provide
neuroprotective benefits in preterm infants, including reduced rates of cerebral palsy and gross motor
dysfunction [72,73,98]. A systematic review of data from five trials (6145 infants) indicated that
antenatal MgSO4 supplementation in women at risk of very preterm birth reduced the risk of cerebral
palsy by 32% (relative risk (RR): 0.68; 95% CI: 0.54, 0.87) [72]. In the 4 studies in which MgSO4 was
administered with neuroprotective intent, the combined rate of death or cerebral palsy was significantly
reduced (RR: 0.85, 95% CI: 0.74, 0.98) [72]. Both single-dose (4 g unrepeated) and multiple-dose (4–6 g
loading followed by 1–2 g/h maintenance) regimens were studied; however, an ideal dosing regimen
remains to be defined [99]. The target sMg concentration also remains unclear.
Data from a small retrospective analysis of sMg levels and motor outcome conducted in 75
premature infants (<1500 g, 25.8 weeks gestation; 20% with MgSO4 supplementation during pregnancy)
demonstrated a statistically significant relationship between lower magnesium levels (≤1.9 mg/dL) in
the neonatal period (average age at first draw, 3.5 days) and abnormal motor exam findings (p = 0.037).
In addition, infants with a lower magnesium level in the neonatal period tended to have a higher
incidence of epilepsy (p = 0.060); however, logistic regression analysis including birth weight and
magnesium concentration was non-significant (possibly due to the relative low sample size of the
study) [100].
In 3 studies, short-term postnatal administration of MgSO4 (250 mg/kg/day for 3 days) has
also demonstrated neuroprotective effects in term infants with severe perinatal asphyxia [101–103].
In the first study, mean sMg was 0.66 mmol/L at admission and 1.60 mmol/L (range, 0.94–2.05) after
48 h [103]. Reported mean sMg concentrations remained at or above 1.2–1.3 mmol/L during the
72-h treatment period and peaked at 2.8–3.2 mmol/L following the third MgSO4 dose in the two
other studies [101,102]. An additional beneficial effect of magnesium supplementation has been also
suggested to reduce bronchopulmonary dysplasia [104] and/or relative hypertension in children [105].
3.6.2. Risk: Adverse Outcomes
MgSO4 supplementation during pregnancy appears to be generally safe for the neonate.
In a meta-analysis of data from five trials and 6145 infants, evidence suggested that magnesium
supplementation during pregnancy reduces the need for ongoing respiratory support and has no
impact on other key pediatric outcomes (e.g., mortality, intraventricular hemorrhage, periventricular
leukomalacia, low Apgar score, need for active resuscitation, convulsions, hypotonia, chronic lung
disease, and postnatal corticosteroid use) [72]. More recently, in their retrospective cohort study of
cardiorespiratory effects of magnesium exposure during pregnancy in preterm neonates (23–28 weeks
gestation), DeJesus et al. (2015) reported similar risk of intubation in the delivery room, respiratory
support during the first day of life, patent ductus arteriosus, and other neonatal outcomes in newborns
with MgSO4 supplementation during pregnancy (n = 1091) relative to those without exposure (n = 453),
as well as lower risk of later (Day 3) mechanical ventilation and hypotension in newborns with MgSO4
supplementation during pregnancy [106]. Indeed, ionized magnesium concentration was inversely
related to umbilical artery pH that could be a confounding factor. Indeed, ionized Ca and ionized
Mg in blood are ionized about 50%, but they are susceptible to the effect of blood pH, with ionization
increasing when blood is on the acid side and decreasing when it is on the alkaline side [106].
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Negative neonatal outcomes have been reported with elevated neonatal ionized magnesium
concentrations [107]. However, ionized magnesium concentration is poorly related to total Mg content
and is more related to acidosis that could be the primary factor of the outcome [108].
Immediate clinical outcomes in preterm infants following magnesium supplementation during
pregnancy were retrospectively evaluated in 475 neonates born between 24 and 32 weeks of
gestation [74]. Serum magnesium level in the first 24 h of life was used to stratify the neonates treated
with magnesium during pregnancy into four subgroups: A (<1.25 mmol/L), B (1.25 to ≤1.75 mmol/L),
C (1.75 to ≤2.25 mmol/L), and D (>2.25 mmol/L). In this study, magnesium during pregnancy was
safe in the immediate postnatal period; however, in the subset of preterm neonates with sMg levels
>2.25 mmol/L, an increased mortality independent of birth weight and gestational age was observed
compared to the subgroup <1.25 mmol/L [74].
Similarly, a retrospective study at a single institution reviewed data from infants born to 6654
women who received MgSO4 during pregnancy for hypertensive disorders during labor and early
postpartum—6 g loading dose over 20 min, followed by 2 g/h adapted to reach a therapeutic range of
2.0–3.5 mmol/L. For all infants, the delay between birth and the last maternal blood sampling was
less than 4 h. Just before delivery, 30% of the mothers had a sMg concentration ranging between
1.5 and 2.0 mmol/L, and 65% had a sMg concentration ranging from 2.0 to 4.6 mmol/L [71]. In this
study, mechanical ventilation in the nursery, intraventricular hemorrhage, and neonatal death were
not significantly associated with maternal sMg concentrations. In contrast, 1- and 5-min Apgar scores,
intubation in the delivery room, admission to special care nursery, and hypotonia were significantly
increased as maternal sMg concentrations increased over 2.5 mmol/L [71]. Considering that cord
blood magnesium levels are directly related to maternal levels, this large study suggests that an sMg
concentration up to 2.5 mmol/L could be safe in preterm infants.
In a study conducted in late-preterm and term infants (≥35 weeks gestation), Greenberg and
colleagues (2011) demonstrated a significant relationship between total hours and total maternal
dose of magnesium and admission to the neonatal intensive care unit (NICU) [109]. In this study,
sMg concentration was not determined in infants not admitted in the NICU; however in the NICU,
36 of 52 neonates (69.2%) had peak sMg levels of 2.05 ± 0.75 mmol/L suggesting that late-preterm
with relative hypermagnesemia were more likely to require respiratory assistance (47.8% versus 32.1%,
respectively; p = 0.4) and/or intravenous fluid supplementation (91.3% versus 39.3%; p < 0.001).
Recently, an additional retrospective cohort study was developed from the Canadian Neonatal
Network [110]. Resuscitation requirements and neonatal outcomes were compared between preterm
infants (23–31 weeks gestation) exposed to intrapartum MgSO4 for neuroprotection (n = 1387),
exposed for combined indications (neuroprotection, preeclampsia, tocolysis, and unknown) (n = 2147),
and unexposed (n = 3868) [110]. This study confirmed that exposure to intrapartum MgSO4 is
not associated with an increased need for intensive delivery room resuscitation in preterm infants
under current delivery room care practices. Indeed, any resuscitation needed and mortality were
significantly reduced in the exposed for neuroprotection and combined indication groups. However,
after adjustment for confounding factors, only death rate remained significantly reduced (adjusted
odds ratio: 0.61 (range: 0.40–0.94) and 0.64 (range: 0.46–0.89), respectively) [110].
It has also be suggested that MgSO4 administration during pregnancy could interfere with the
closure of the ductus arteriosus [111]. In a retrospective study in 160 preterm infants (<28 weeks
gestation) MgSO4 administration during pregnancy significantly reduced the closure of the ductus
arteriosus following prophylactic indomethacin at birth compared to the control group; however, the
efficacy of indomethacin treatment was similar in the two groups [111]. Moreover no differences
have been observed in randomized trials using antenatal MgSO4 administrations for neuroprotection
(PREMAG study). The threshold level of sMg concentration significantly impairing the spontaneous
closure of the patent ductus arteriosus remains to be determined.
Limited reports in preterm and term infants are available to evaluate the main clinical side effects
of hypermagnesemia. Ali and colleagues (2003) described two cases of acute hypermagnesemia
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in premature infants resulting from malfunction of an automated total parenteral nutrition mixing
device [112]. Observed effects included hypotension, QT interval prolongation, intraventricular
conduction delay, respiratory depression, neuromuscular blockade, and coma [112]. In both infants, sMg
levels upon admission were extremely high (21.6 mmol/L and 22.5 mmol/L, respectively) [112]. Similar
effects (e.g., severe hypotension, lethargy, hypotonia, diminished deep tendon reflexes, respiratory
depression, apnea, and sluggish pupillary reflexes) have been described in premature neonates
with hypermagnesemia (17.8–18.4 mmol/L) of unknown etiology and no history of magnesium
supplementation [113,114]. In 2013, the FDA provided a safety announcement recommending against
prolonged use of MgSO4 to stop preterm labor as administration of MgSO4 injection to pregnant women
longer than 5–7 days can cause low calcium levels and bone problems in the developing fetus or neonate,
including thin bones (i.e., osteopenia) and bone breaks (i.e., fractures) [115].
Overall, these data suggest that neonates can tolerate during a short time a relatively wide
range of sMg concentrations, without increased risk of adverse outcomes primarily associated with
substantially increased sMg.
3.7. Implications for Postnatal Magnesium Supplementation in Preterm Infants
Clinical practice guidelines for the feeding of newborns have been regularly revised over recent
decades, reflecting our improved understanding of nutrient requirements early in life [17,116–125].
Infants fed by the enteral route require higher levels of magnesium supplementation, because only
approximately 30% to 50% of ingested magnesium is absorbed [11]. Taking this into consideration,
the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)
Committee on Nutrition in 2010 and an international group of experts in 2014 recommended that
VLBW infants receiving enteral nutrition target a magnesium intake of 0.33–0.62 mmol/kg/day
(8–15 mg/kg/day) [17,118]. Previous guidelines for enteral nutrition recommended that magnesium in
enteral feedings could be increased as the preterm infant matured (from 0.20–0.25 mmol/kg/day for
the first seven days to 0.20–0.40 mmol/kg/day from stabilization to term and 0.20–0.60 mmol/kg/day
from term to one year) [119,120]. Both noted that required magnesium supplementation levels
may vary depending on the feeding of other minerals that could influence the bioavailability of
magnesium [119,120]. Considering a mean absorption rate around 50% [126], metabolizable magnesium
can be estimated as 0.1–0.3 mmol/kg/day that could be used for adequate intakes in parenteral nutrition.
Recommendations for parenteral magnesium intake in preterm infants are limited and vary
considerably; however, most propose the use of lower parenteral magnesium doses relative to those
used in enteral supplementation. The American Society for Parenteral and Enteral Nutrition has
recommended 0.15–0.25 mmol/kg/day in both preterm neonates and in infants and children weighing
up to 50 kg [116,117]. ESPGHAN guidelines (2005) do not provide recommendations for parenteral
magnesium intake in preterm infants but suggest supplementation at a rate of 0.2 mmol/kg/day
for infants 0–6 months of age [123]. In a more recent clinical nutrition webinar series (in 2013),
higher targets were identified for neonates weighing <2 kg (0.175–0.3 mmol/kg/day) than for
neonates weighing >2 kg (0.125–0.25 mmol/kg/day) [127,128]. Recent recommendations put forth
by the Chinese Society of Parenteral and Enteral Nutrition are slightly higher (0.3–0.4 mmol/kg/day
in premature infants and 0.4–0.5 mmol/kg/day in term infants) [121]. However, a ready-to-use
parenteral solution providing 0.38 mmol/kg/day was recently retrieved from the market in 2013
due to a risk of hypermagnesemia and was replaced by the same solution providing a maximum
of 0.21 mmol/kg/day [129]. Therefore, for VLBW infants, a reduction of the magnesium intake
has been suggested during the first day of life; thus, Mimouni and colleagues (2014) recommend
0–0.12 mmol/kg/day on the first day of life and 0.3–0.4 mmol/kg/day thereafter [17].
According to the data available on parenteral nutrition in preterm infants, as presented before,
magnesium supplies may be provided from the first day of life in preterm infants and progressively
increased during the first week in relation to the protein (amino acid) and the energy intakes. In the
range of the actual recommendations (0.10–0.40 mmol/kg/day), safe levels of sMg concentration are
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observed. Nevertheless, in light of the apparent variability in magnesium levels reported in the preterm
population, regular serum monitoring should be used to tailor supplementation for the individual
patient. This is of particular importance in infants with a history of magnesium supplementation
during pregnancy, infants receiving indomethacin or ibuprofen for patent ductus arteriosus prevention
or treatment, and infants with transitory renal failure.
3.8. Limitations
These meta-analyses were limited by high levels of heterogeneity and a limited number of
available studies reporting sMg concentrations in mothers and neonates. Although heterogeneity was
not explored statistically, reasons for this variance include differences in magnesium intake during
pregnancy, postnatal magnesium intake, number of samples taken, sample timing, gestational age,
lack of standardized analytical methods to determine magnesium level, and exclusion/inclusion
criteria relevant to medical conditions (e.g., hypertension, preeclampsia, diabetes, and AIDS).
4. Summary and Recommendations
Serum magnesium levels vary broadly in preterm infants and are influenced not only by
maternal factors, but also by health status (e.g., renal function), concomitant nutrient intake,
and drug administration. Available data suggest that normal mean sMg levels in preterm infants
during the first week of life was higher than that in the cord blood and could be estimated as
0.88 mmol/L with a reference interval ranging from 0.46 to 1.30 mmol/L (Figure 7). In infants
with magnesium supplementation during pregnancy, as well as in preterm infants with relative renal
failure, sMg concentrations up to 2.0 mmol/L appear to be well tolerated, requiring adequate survey
and minimal intervention. It is notable that these data were fairly consistent, despite the lack of
standardized analytical methods of magnesium level determination. The considerable variance in
the recommendations for enteral and parenteral magnesium intake in preterm infants reflects the
limited knowledge of magnesium requirements in this population; thus, regular serum monitoring
is crucial to maintaining adequate magnesium levels in the individual patient. In addition, due to
the demonstrated neuroprotective effect with antenatal administration of MgSO4, it is proposed to
conduct a randomized clinical trial evaluating different dose regimens of magnesium in parenteral
nutrition on neurodevelopmental outcomes and potential side effects in VLBW infants.
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